首页 > 市场调查报告书 > 製药

精神疾病

发作性睡病治疗市场规模、份额和成长分析（按治疗类型、疾病类型和地区划分）—产业预测（2026-2033 年）

市场调查报告书

商品编码

1899392

发作性睡病治疗市场规模、份额和成长分析（按治疗类型、疾病类型和地区划分）—产业预测（2026-2033 年）

Narcolepsy Drugs Market Size, Share, and Growth Analysis, By Therapeutic Type (Sodium Oxybate, Central Nervous System Stimulants), By Disease Type (Daytime Extreme Sleepiness, Catalplexia), By Region -Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，嗜睡症治疗市场规模将达到 40.5 亿美元，到 2025 年将达到 44.3 亿美元，到 2033 年将达到 91.7 亿美元，在预测期（2026-2033 年）内复合年增长率为 9.5%。

由于人们对心理健康的认识不断提高以及睡眠障碍盛行率的上升，嗜睡症治疗市场正在经历变革。嗜睡症诊断率的上升、对创新治疗方法研发的投资以及对提高生活品质日益增长的需求，是推动市场扩张的关键因素。监管机构正在加快医药品认证过程，以满足尚未满足的医疗需求，这为製药公司提供了巨大的成长机会。此外，药物发现和研发技术的进步有望促进嗜睡症疗法在全球的普及。然而，认知度低、潜在的副作用以及来自非药物疗法的竞争等挑战可能会阻碍市场成长。平衡这些趋势对于相关人员应对未来的趋势和需求至关重要。

嗜睡症治疗市场驱动因素

人们对心理健康的日益关注显着提升了对包括嗜睡症在内的各种疾病的理解和认知。随着压力和焦虑的加剧，应对这些挑战也日益受到重视。针对心理健康问题的新措施和计画将增强嗜睡症治疗市场的未来潜力。这种对寻找有效治疗方案的日益重视预计将推动对创新药物的需求，最终强化市场格局，并提高嗜睡症患者的照护品质。

嗜睡症治疗市场的限制

由于大众对发作性睡病的症状和影响了解有限，尤其是在发展中和欠发达地区，发作性睡病药物市场面临严峻挑战。这种知识不足导致许多发作性睡病患者未能得到诊断和治疗，对发作性睡病药物的需求产生了负面影响。有针对性的宣传活动和宣传活动有助于提高公众对该疾病及其治疗方案的认识，从而可能缓解这一限制并扩大发作性睡病药物市场。提高公众意识将有助于早期诊断，改善患者的治疗效果，最终推动市场成长。

嗜睡症治疗市场趋势

嗜睡症药物市场正经历着基于Orexin治疗方法的显着发展，这主要得益于此类疗法有望更有效地解决疾病的根本原因，同时最大限度地减少副作用。随着製药公司加强对Orexin受体促效剂研发的投入，这些创新治疗方法正日益受到医疗服务提供者和患者的关注。这一市场趋势反映了人们为拓展治疗选择、提高患者生活品质所做的努力。随着基于Orexin的治疗方法逐渐成为传统治疗方法的可行替代方案，预计未来几年嗜睡症药物市场将迎来显着成长和发展。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

Jazz Pharmaceuticals plc
Teva Pharmaceutical Industries Ltd.
Bioprojet Pharma SARL
Novartis International AG
Takeda Pharmaceutical Company
Avadel Pharmaceuticals
Mylan NV（now part of Viatris）
Aurobindo Pharma
Glenmark Pharmaceuticals
Lupin Pharmaceuticals
Otsuka Pharmaceutical
Biogen
Theravance Biopharma
Ligand Pharmaceuticals
Flamel Technologies（now Avadel Pharmaceuticals）
Biocodex
Sun Pharmaceutical Industries
Cipla Limited
Dr. Reddy's Laboratories
Pfizer Inc.

简介目录

Product Code: SQMIG35I2087

Narcolepsy Drugs Market size was valued at USD 4.05 Billion in 2024 and is poised to grow from USD 4.43 Billion in 2025 to USD 9.17 Billion by 2033, growing at a CAGR of 9.5% during the forecast period (2026-2033).

The narcolepsy drugs market is poised for transformation driven by heightened mental health awareness and the rising incidence of sleep disorders. An increasing number of narcolepsy diagnoses, investments in innovative treatment development, and a growing demand for lifestyle enhancements are key drivers for market expansion. Regulatory bodies are expediting drug approval processes to address unmet medical needs, offering significant opportunities for pharmaceutical companies. In addition, advancements in drug discovery and development technologies are expected to enhance global adoption of narcolepsy medications. However, challenges such as limited awareness, potential side effects, and competition from non-pharmacological treatments may impede growth prospects in the market. Balancing these dynamics will be crucial for stakeholders in navigating future trends and demands.

Top-down and bottom-up approaches were used to estimate and validate the size of the Narcolepsy Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Narcolepsy Drugs Market Segments Analysis

Global Narcolepsy Drugs Market is segmented by Disease Type, Therapeutics Type, and region. Based on Disease Type, the market is segmented into Daytime Extreme Sleepiness, Cataplexia, and Other Disease Type. Based on Therapeutics Type, the market is segmented into Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Other Therapeutic Type. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Narcolepsy Drugs Market

The growing awareness of mental health has significantly contributed to the understanding of various disorders, including narcolepsy, which has become increasingly prevalent. As stress and anxiety rates escalate, so does the focus on addressing these challenges. New initiatives and programs aimed at tackling mental health issues will likely enhance the future potential of the narcolepsy drugs market. This heightened emphasis on finding effective solutions for patients suffering from narcolepsy is expected to drive demand for innovative medications, ultimately strengthening the market landscape and improving the quality of care for those affected by this condition.

Restraints in the Narcolepsy Drugs Market

The narcolepsy drugs market faces significant challenges due to limited awareness of the symptoms and effects of narcolepsy across various regions, particularly in developing and underdeveloped areas. This lack of knowledge results in many individuals with narcolepsy remaining undiagnosed and untreated, which adversely impacts the demand for narcolepsy medications. By implementing targeted awareness programs and campaigns, it is possible to educate the public about the condition and its treatment options, thereby helping to alleviate this constraint and potentially enhancing the market for narcolepsy drugs. Increased awareness can lead to earlier diagnosis and improved patient outcomes, ultimately boosting market growth.

Market Trends of the Narcolepsy Drugs Market

The narcolepsy drugs market is witnessing a significant shift towards the development of orexin-based therapies, driven by their potential to more effectively address the disorder's underlying causes with fewer adverse effects. As pharmaceutical companies increasingly invest in research and development of orexin receptor agonists, these innovative treatments are poised to gain traction among both healthcare providers and patients. This market trend reflects a broader commitment to enhancing treatment options and improving patient quality of life. As orexin-based therapies emerge as a viable alternative to traditional treatments, the narcolepsy drugs market is likely to experience substantial growth and evolution in the coming years.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Regulatory Analysis
Case Study Analysis
Clinical Trials

Narcolepsy Drugs Market, By Disease Type

Market Overview
Daytime Extreme Sleepiness
Cataplexia
Other Disease Type

Narcolepsy Drugs Market, By Therapeutics Type

Market Overview
Central Nervous System Stimulants
Tricyclic Antidepressants
Sodium Oxybate
Selective Serotonin Reuptake Inhibitor
Other Therapeutic Type

Narcolepsy Drugs Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Jazz Pharmaceuticals plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioprojet Pharma SARL
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avadel Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (now part of Viatris)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glenmark Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Theravance Biopharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ligand Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Flamel Technologies (now Avadel Pharmaceuticals)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocodex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments